A Phase 1 study of BAY3498264 alone or with sotorasib in advanced solid cancers with KRASG12C mutation
Recruiting Phase 1 NCT06659341
Study Description
A study to evaluate the safety and dosage of a new drug called BAY3498264, alone or in combination with sotorasib, for treating advanced solid cancers with a specific genetic change (KRASG12C mutation)
Study Details
- Registry ID:
- NCT06659341
- Conditions:
- Advanced Solid Tumors Harboring KRAS G12C Mutation
- Phase:
- Phase 1
- Target Enrollment:
- 104 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (28 sites)
-
Institut Català d'Oncologia Hospitalet
L Hospitalet De Llobregat, Barcelona, Spain -
Institut Catala D'oncologia - Hematologia
L Hospitalet De Llobregat, Barcelona, Spain -
Institut Catala D'oncologia | Hospitalet | Oncologia
L'Hospitalet de Llobregat, Barcelona, Spain -
Institut Catala D'oncologia | Oncologia
L'Hospitalet de Llobregat, Barcelona, Spain -
Institut Catala D'oncologia | Hematologia
L'Hospitalet de Llobregat, Barcelona, Spain -
Institut Catala D'oncologia - Hematologia
L'Hospitalet de Llobregat, Barcelona, Spain -
Hospital Universitari Vall d'Hebron- Oncology Service
Barcelona, Spain -
Institut Catala D'oncologia | Hospitalet | Oncologia
Barcelona, Spain -
Hospital Universitari Vall D Hebron | Oncologia
Barcelona, Spain -
Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO)
Barcelona, Spain -
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Rome, Lazio, Italy -
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Roma, Lazio, Italy -
Gruppo Humanitas - Humanitas Research Hospital - Cancer Center
Rozzano, Italy -
Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
Rozzano, Italy -
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Roma, Italy -
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton
Sutton, Surrey, United Kingdom -
The Christie NHS Foundation Trust - Christie Hospital
Manchester, United Kingdom -
The Christie NHS Foundation Trust - Christie Hospital
Manchester, Greater Manchester, United Kingdom -
Rigshospitalet - Kræftbehandling
Copenhagen OE, Denmark -
Rigshospitalet - Kræftbehandling
Copenhagen, Capital Region, Denmark -
Rigshospitalet Copenhagen University Hospital | Oncology Department
Copenhagen, Capital Region, Denmark -
Rigshospitalet Copenhagen University Hospital | Oncology Department
Copenhagen, Capital Region / Region Hovedstaden, Denmark -
Rigshospitalet - Kræftbehandling
Copenhagen, Denmark -
Cabrini Health Oncology Research
Malvern, Victoria, Australia -
Peninsula and Southeast Oncology
Frankston, Victoria, Australia -
Border Medical oncology - Albury Wodonga Regional Cancer Centre
Albury, New South Wales, Australia -
Macquarie University Hospital
Macquarie Park, New South Wales, Australia -
Macquarie University Hospital - Oncology Department
Macquarie Park, New South Wales, Australia
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.